Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns

Regeneron has halted the higher-dose arms of its phase 3 fasinumab trials on the recommendation of a data monitoring committee. The committee made the call after assessing the risk-benefit profile of the osteoarthritis regimens based on data generated to date.